Kistler-Tiffany Companies’s Regeneron Pharmaceuticals REGN Stock Holding History

Kistler-Tiffany Companies’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$378K	Sell	526 -24	-4%	-$18.5K	0.06%	244
2023 Q1	$452K	Buy	550 +191	+53%	+$144K	0.09%	178
2022 Q4	$259K	Buy	359 +215	+149%	+$159K	0.05%	218
2022 Q3	$99K	Buy	144 +34	+31%	+$21.4K	0.02%	286
2022 Q2	$65K	Hold	110	–	–	0.01%	349
2022 Q1	$77K	Hold	110	–	–	0.01%	338
2021 Q4	$69K	Hold	110	–	–	0.01%	339
2021 Q3	$67K	Buy	110 +18	+20%	+$11.2K	0.02%	335
2021 Q2	$51K	Buy	92 +5	+6%	+$2.53K	0.01%	367
2021 Q1	$41K	Hold	87	–	–	0.01%	357
2020 Q4	$42K	Buy	87 +37	+74%	+$20K	0.01%	320
2020 Q3	$28K	Sell	50 -9	-15%	-$5.46K	0.01%	350
2020 Q2	$37K	Buy	59 +20	+51%	+$11.4K	0.01%	285
2020 Q1	$15K	Hold	39	–	–	0.01%	399
2019 Q4	$15K	Hold	39	–	–	0.01%	407
2019 Q3	$11K	Hold	39	–	–	﹤0.01%	439
2019 Q2	$12K	Hold	39	–	–	﹤0.01%	423
2019 Q1	$16K	Hold	39	–	–	0.01%	375
2018 Q4	$15K	Hold	39	–	–	0.01%	350
2018 Q3	$16K	Buy	+39	New	+$14.8K	0.01%	379
2016 Q3	–	Sell	-3	Closed	-$1K	–	670
2016 Q2	$1K	Buy	+3	New	+$1.16K	﹤0.01%	601

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kistler-Tiffany Companies's REGN Position: Q2 2023 in Review

Kistler-Tiffany Companies reduced its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2023, selling an estimated $18.5K and leaving 526 shares worth $378K. The position accounts for 0.06% of the portfolio, ranked #244.

Kistler-Tiffany Companies first reported a position in REGN in Q2 2016 and has held it in 21 quarters since. The position peaked at $452K in Q1 2023. 1,166 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Kistler-Tiffany Companies held 526 shares of Regeneron Pharmaceuticals worth $378K as of Q2 2023.
Kistler-Tiffany Companies sold 24 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $18.5K.
Regeneron Pharmaceuticals made up 0.06% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #244 holding.
Kistler-Tiffany Companies first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 21 quarters since.
Kistler-Tiffany Companies's Regeneron Pharmaceuticals position peaked at $452K in Q1 2023.
1,166 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.